NeRRe Therapeutics
NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin (NK)-1 receptor antagonist, for the treatment of chronic cough hypersensitivity disorders, particularly in patients with idiopathic pulmonary fibrosis (IPF). The company is focused on the cough associated with this lung disease, for which there are currently no approved treatments.
- Orvepitant for chronic cough
- Neurokinin (NK)-1 receptor antagonists
Locations
Digital Popularity
Social Media
LinkedIn879 Followers
Competitors
Stevenage Bioscience Catalyst is a leading location for therapeutic innovation, providing an ideal environment for growth within a supportive and networked community.
Company Details
NeRRe Therapeutics is operated by Nerre Therapeutics Ltd and is a Active company incorporated on 19 January 2012 with the registered office located in Stevenage, Hertfordshire. Nerre Therapeutics Ltd was registered 13 years ago.
Status
Active
Size
Micro
Directors
7
Age
13 years old
Employees
14
Turnover
Unreported
Total Assets
£6.3M
Cash in Bank
£4.67M
Total Liabilities
-£26.76M
Teams
7
5
4
1
Vice President Clinical Operations • Joined Apr 2022
Senior Vice President, CMC - NeRRe Therapeutics • Joined Aug 2018
Co-founder & Chief Scientific Officer • Joined Dec 2012
CEO • Joined Sep 2015
Chairman Of The Board • Joined Sep 2017
Office Manager/Executive Assistant • Joined Nov 2018
Chief Medical Officer • Joined Jan 2017
Vice President Clinical Operations • Joined Apr 2022
Co-founder & Chief Scientific Officer • Joined Dec 2012
CEO • Joined Sep 2015
Office Manager/Executive Assistant • Joined Nov 2018
Chief Medical Officer • Joined Jan 2017
Vice President Clinical Operations • Joined Apr 2022
Co-founder & Chief Scientific Officer • Joined Dec 2012
CEO • Joined Sep 2015
Chairman Of The Board • Joined Sep 2017
Senior Vice President, CMC - NeRRe Therapeutics • Joined Aug 2018